Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
(NASDAQ: MNPR) Delayed: 81.77 +13.11 (19.09%)
Previous Close $68.66    52 Week High $ 
Open $68.21    52 Week Low $ 
Day High $83.57    P/E N/A 
Day Low $68.21    EPS $ 
Volume 278,006